What Dafiro Treats: Main Uses and Benefits

Dafiro is commonly used for the long-term management of high blood pressure in adults. It is applied across domains where additional symptomatic support is needed and is relevant in conditions characterized by periods of heightened symptoms, specifically when a single medication may not be sufficient to manage high blood pressure.

The medicine is relevant for easing symptoms related to systemic imbalance and is applied across domains where additional symptomatic support is needed. It is used for high blood pressure that requires a combination of treatments, offering relief for elevated readings and support for patient well-being. This contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“The medication contributes to easing the overall symptom load and may assist with maintaining functional stability.”

Quick Fact: Management for Elevated Blood Pressure Readings

This medication may assist with reducing high blood pressure by combining two components, and is used in settings marked by temporary physiological imbalance.

Regulatory References

1. European Commission's product information for Dafiro

Eligibility: Who Can and Cannot Use Dafiro?

Dafiro (amlodipine/valsartan) is officially approved for use only in adult patients with essential hypertension whose blood pressure is not adequately controlled by a single medicine. Regulatory documentation strictly defines populations who must not use the medicine (contraindications) and those for whom use is restricted.

---

Absolute Non-Eligibility (Contraindications)

Classification	Population/Condition
Hypersensitivity	Known allergy to the active ingredients, dihydropyridine derivatives, or excipients.
Pregnancy	Women in the second and third trimesters of pregnancy.
Hepatic Function	Patients with severe hepatic impairment, including biliary cirrhosis or cholestasis.
Cardiovascular Status	Those experiencing severe hypotension, shock, or obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis).
Drug Interaction	Patients with diabetes or renal impairment (GFR < 60 mL/min/1.73m²) taking aliskiren-containing products.

---

Restricted and Conditional Use

Population Group	Regulatory Status
Pediatric Use	Not recommended for children and adolescents below 18 years (safety/efficacy not established).
Organ Function	Caution is required in mild to moderate hepatic impairment and in those with unilateral or bilateral renal artery stenosis.
Physiological Status	Use is not recommended during the first trimester of pregnancy and during breastfeeding.

These official rules define the specific regulatory boundary for Dafiro use, establishing eligibility based strictly on the absence of contraindications and the approved adult demographic.

Interactions with other medicines and products

The interaction profile of Dafiro is defined by the effects of its two components, Amlodipine and Valsartan, with other co-administered substances, as documented in official regulatory labeling.

Contraindicated and Non-Recommended Combinations

The dual-action of Valsartan (an Angiotensin II Receptor Blocker) with other agents that block the Renin-Angiotensin-Aldosterone System (RAAS) carries specific constraints.

• Aliskiren: Co-administration is formally contraindicated in patients with diabetes mellitus or specific renal impairment (Glomerular Filtration Rate (GFR) < 60 mL/min/1.73 m^2).
• ACE Inhibitors: Co-administration is contraindicated in patients with diabetic nephropathy.
• Potassium-Altering Agents: Combining Valsartan with substances like Potassium supplements, Potassium-sparing diuretics, salt substitutes containing potassium, or Heparin is not recommended due to the risk of hyperkalaemia (increased serum potassium).
• Lithium: Concomitant use with Lithium is not recommended due to the potential for increased serum Lithium concentrations and toxicity.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions that modify the drug's systemic exposure or its effects are documented:

• CYP3A4 Inhibitors: Potent inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir) and moderate inhibitors like Diltiazem may significantly increase the plasma concentration of Amlodipine.
• Transporter Inhibitors: Inhibitors of the hepatic uptake transporter OATP1B1 (e.g., Rifampin, Cyclosporine) or the efflux transporter MRP2 (e.g., Ritonavir) may increase the systemic exposure to Valsartan.
• Simvastatin: A dose restriction applies; co-administration requires that the Simvastatin dose must not exceed 20 mg daily.
• NSAIDs: Co-administration with Non-steroidal Anti-inflammatory Drugs (NSAIDs) may cause attenuation of the antihypertensive effect and increase the risk of worsening renal function.
• Alcohol: Consumption of alcohol may increase the risk of dizziness.

No timing separation requirements are noted for administration with food, as the bioavailabilities of the active components are not altered.

Dafiro is a fixed-dose combination medication that influences cardiovascular regulation through two distinct and complementary mechanisms, mediated by its components, valsartan and amlodipine.

Modulation of the Renin-Angiotensin System

The component valsartan acts as an Angiotensin II Receptor Blocker (ARB). It selectively engages and antagonizes the Type 1 Angiotensin II ( AT1) receptors, primarily located on vascular smooth muscle cells and in the adrenal gland. By blocking these specific receptors, valsartan suppresses the signaling cascade typically initiated by Angiotensin II, which normally promotes vasoconstriction and aldosterone release. The mechanistic consequence is a shift in vascular tone and a modification of the pathways governing fluid and electrolyte balance.

---

Inhibition of Calcium Ion Influx

The component amlodipine is a dihydropyridine calcium channel blocker. It selectively binds to and inhibits the transmembrane entry of calcium ions through L-type voltage-dependent calcium channels in the cell membrane of vascular smooth muscle. This action prevents the required intracellular calcium concentration increase needed for muscle contraction. The resulting physiological effect is the facilitation of passive relaxation of the vascular smooth muscle, which alters total peripheral resistance.

Official Administration Guidelines

The use of Dafiro (amlodipine/valsartan) is governed by specific instructions defining the standard pattern for this fixed-dose combination therapy. It is used in adult patients whose blood pressure is not adequately controlled on monotherapy.

Feature	Official Guideline
Route of Administration	The medicine is strictly intended for oral use, delivered as a film-coated tablet.
Dosing Schedule	The standard recommended dose is one tablet once daily. The maximum daily dose is 10/320 mg (amlodipine/valsartan).
Timing & Preparation	The tablet may be administered with or without food and should be taken with some water.
Dose Adjustment Interval	When changes are necessary, the dosage should only be increased after a minimum of 1 to 2 weeks following the prior adjustment.
Specific Populations	Mild to Moderate Hepatic Impairment: The valsartan component maximum is limited to 80 mg for non-cholestatic cases. Pediatric Use: Safety and efficacy in patients under 18 years of age have not been established.

The official use protocol is structured around a long-term, once-daily pattern. This systematic approach establishes that the majority of the antihypertensive effect is typically achieved within two weeks of initiation or dose change, mandating a precise interval for dosage evaluation. The constraint on the maximum component dose in hepatic impairment ensures that administration adheres to established physiological limits for specific patient populations.

Pharmacological Mechanism Research

Dafiro is a fixed-dose combination containing amlodipine (a calcium channel blocker) and valsartan (an angiotensin II receptor antagonist). The combination is designed to influence blood pressure by providing two distinct mechanisms. Amlodipine works by inhibiting calcium ion influx into the vascular smooth muscle, which promotes blood vessel relaxation. Valsartan acts by blocking the effects of the hormone angiotensin II, which helps to widen blood vessels. Studies investigated this dual mechanism, reporting findings consistent with these two distinct actions.

---

Core Clinical Efficacy Trials

Essential Hypertension Studies

Clinical trials have examined whether Dafiro influences blood pressure in patients with essential hypertension (high blood pressure with no known cause). Key registrational trials compared the combination of amlodipine and valsartan against placebo and against the individual components taken alone. These studies generally reported a greater reduction in both systolic and diastolic blood pressure with the combination compared to either amlodipine or valsartan used as monotherapy.

In studies involving patients whose blood pressure was not adequately controlled on a single component (either amlodipine or valsartan), adding the second component was associated with further reductions in blood pressure over an eight-week period. Research protocols often included the evaluation of different dose levels and fixed-dose combinations.

---

Safety and Tolerability Profile

Safety data was collected across all phases of clinical research. Common side effects observed in trials included peripheral edema (swelling of the hands or feet), headache, and fatigue. The incidence of edema seen with amlodipine alone was generally reported as less frequent when combined with valsartan. Rare, but serious, adverse events were monitored throughout the trials and reported to regulatory agencies.

Common questions about Dafiro (FAQ)

Q: How quickly should I expect Dafiro to start working?

According to official product information, the initial blood pressure-lowering effect typically begins within a few hours of administration. However, the maximum reduction in blood pressure is generally achieved after 2 to 4 weeks of consistent, daily administration.

Q: Is Dafiro a once-a-day medication?

Yes, official documents describe the standard recommended dosing as one tablet taken once daily. This systematic approach is structured around a long-term, once-daily administration pattern.

Q: Is ankle swelling a common side effect of Dafiro?

Swelling, which is often referred to by its clinical term, oedema, is described in official safety sources as a common side effect. This typically appears as peripheral oedema, which includes swelling of the hands or feet, such as ankle swelling.

Q: Does Dafiro cause fatigue or tiredness in many patients?

Fatigue is listed in the official safety documentation as a common adverse reaction of the medicine. The full safety information can provide details on the reported frequency of this reaction.

Q: Can taking Dafiro affect my kidney function tests?

Official safety information recommends the monitoring of kidney (renal) function. Monitoring of kidney function markers is suggested for certain patient populations.

Q: Is it normal to feel dizzy when first starting Dafiro?

Dizziness, or vertigo, is listed in official documents as an uncommon side effect of the medicine. Caution is generally advised regarding activities that require alertness, as dizziness is a reported side effect.

Q: Can men taking Dafiro experience sexual side effects?

Official safety documents list erectile dysfunction as a rare adverse reaction. This is the specific sexual side effect documented in regulatory sources.

Q: What percentage of patients report headaches when starting Dafiro?

Headache is classified in official safety documents using the frequency term 'common' rather than a specific percentage figure. The classification 'common' is used in regulatory documentation to describe its frequency.

Q: Does Dafiro require regular blood tests or monitoring?

Official safety information recommends the monitoring of blood pressure, kidney function, and serum potassium levels. This monitoring is suggested, especially for high-risk patients.

Q: Can Dafiro be stopped suddenly, or should it be gradual?

Regulatory documents note that abrupt withdrawal of the valsartan component (one of the medicine's ingredients) has not been associated with a rebound increase in blood pressure or other adverse clinical events in studies.

Q: Do older patients generally use the same dose of Dafiro as younger adults?

Official dosing documents state that no dose adjustment to the starting dose is generally required for older patients. However, starting with the lowest available dose of the amlodipine component should be considered, and caution is advised in official documentation when the dosage is increased.

Q: Are there any common over-the-counter pain relievers that interact with Dafiro?

Official documents warn that Non-steroidal Anti-inflammatory Drugs (NSAIDs), which include several common over-the-counter pain relievers, may interact with the medicine. This interaction could potentially reduce the blood pressure-lowering effect and increase the risk of worsening kidney function.

Q: Do any specific foods or drinks need to be avoided while taking Dafiro?

Official safety information notes that consumption of alcohol may increase the risk of dizziness. Additionally, strong or moderate inhibitors of the CYP3A4 enzyme, such as grapefruit juice, can significantly increase the concentration of the amlodipine component due to a documented potential for interaction.

Q: What happens if a dose of Dafiro is missed?

If a dose is missed, regulatory guidance generally suggests continuing with the next dose at the regular scheduled time. The guidance is to not take a double dose to compensate for the missed one.

Q: Can Dafiro be used by people with a history of heart failure?

Official documents advise that caution is required when the medicine is used in patients with serious congestive heart failure. The medicine is generally used with caution in these specific patient populations.

Q: Does the package insert mention a risk of angioedema with Dafiro?

Yes, the potential for angioedema is mentioned in the regulatory safety documentation as a serious adverse reaction. Angioedema is a severe swelling of the face, lips, tongue, or throat.

Q: Are there known interactions between Dafiro and grapefruit juice?

Official documents note that strong or moderate inhibitors of the CYP3A4 enzyme, which includes grapefruit juice, can significantly increase the concentration of the amlodipine component. This potential interaction is a documented safety concern.

Q: Does Dafiro affect blood sugar levels?

The official product information lists hyperglycemia (high blood sugar) as a very rare adverse reaction. This is documented under metabolism and nutrition disorders.

Q: Is Dafiro considered a long-term treatment?

Yes, the official use protocol is structured around a long-term, once-daily administration pattern for the management of chronic high blood pressure.

Q: Do research studies show Dafiro reduces the risk of stroke?

The medicine is indicated to lower blood pressure, which, as stated in regulatory documents, is essential because lowering blood pressure reduces the overall risk of serious cardiovascular events, including strokes and heart attacks.

Q: Is Dafiro considered a first-line treatment for high blood pressure?

Official documents state that the medicine is used in adult patients whose blood pressure is not adequately controlled with a single blood pressure medicine (monotherapy). This indicates it is typically used as a follow-up or combination treatment.

Q: Can patients with diabetes use Dafiro for their high blood pressure?

The medicine is specifically contraindicated (must not be used) in patients with diabetes mellitus who are also taking aliskiren-containing products. For other patients with diabetes not taking aliskiren, diabetes itself is not listed as an absolute contraindication.

Q: Does Dafiro interact with supplements like potassium or calcium?

Official safety information states that the use of potassium supplements or salt substitutes containing potassium is not recommended. This is due to the potential risk of hyperkalaemia (increased serum potassium).

Q: What should be done if an allergic reaction to Dafiro is suspected?

In the event of a suspected serious adverse reaction like angioedema (severe swelling of the face, lips, or throat), immediate discontinuation is noted as a requirement in the regulatory guidelines.

Q: Are there any restrictions on driving or operating machinery while taking Dafiro?

Caution is advised regarding driving or operating machinery, as the medicine can cause side effects such as dizziness or fatigue, which could affect your concentration and physical ability.

Q: Is Dafiro safe to take with alcohol, according to official sources?

Official safety information notes that consumption of alcohol may increase the risk of dizziness. Official documents describe the potential risk associated with alcohol use.

Q: Is Dafiro suitable for patients who are also taking cholesterol-lowering drugs?

A dose restriction applies to the cholesterol-lowering medicine Simvastatin. If co-administered, the Simvastatin dose must not exceed 20 mg daily, as documented in the official interactions information.

Q: Is dry cough a known side effect of the olmesartan component in Dafiro?

Cough is listed in official safety documents as an uncommon adverse reaction. The product information uses this frequency classification to describe the likelihood of the side effect.

Q: What is the shelf life or storage requirements for Dafiro tablets?

Official regulatory guidelines require the medicine to be stored at controlled room temperature, specifically not exceeding 30 C (86 F). The tablets must also be protected from moisture and kept in their original package.

Q: Why might a doctor switch a patient from another blood pressure drug to Dafiro?

The medicine is indicated for use in adult patients whose blood pressure is not adequately controlled with a single blood pressure medicine (monotherapy). This is the primary regulatory context for using this fixed-dose combination therapy.

How to Store and Dispose of Dafiro

Official regulatory guidelines require Dafiro (amlodipine and valsartan) tablets to be stored at controlled room temperature, with a maximum limit not exceeding 30 C (86 F). The medication must be protected from moisture and kept dry; therefore, it should be stored in the original container/package until use.

Storage and Disposal Rules

Condition	Requirement
Temperature	Do not store above 30 C (86 F).
Protection	Protect from moisture and keep dry in the original package.
Child Safety	Keep out of the sight and reach of children.
Disposal	Follow local regulatory guidelines, utilizing a drug take-back program or mixing with an undesirable substance for household trash.

Unused or expired Dafiro must not be discarded via wastewater. The official disposal procedures are designed to maintain product stability and ensure public safety.